1. Home
  2. APLM vs WKHS Comparison

APLM vs WKHS Comparison

Compare APLM & WKHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • WKHS
  • Stock Information
  • Founded
  • APLM 2016
  • WKHS 2007
  • Country
  • APLM United States
  • WKHS United States
  • Employees
  • APLM N/A
  • WKHS N/A
  • Industry
  • APLM Blank Checks
  • WKHS Auto Manufacturing
  • Sector
  • APLM Finance
  • WKHS Consumer Discretionary
  • Exchange
  • APLM Nasdaq
  • WKHS Nasdaq
  • Market Cap
  • APLM 6.9M
  • WKHS 6.0M
  • IPO Year
  • APLM N/A
  • WKHS N/A
  • Fundamental
  • Price
  • APLM $6.14
  • WKHS $1.45
  • Analyst Decision
  • APLM
  • WKHS Hold
  • Analyst Count
  • APLM 0
  • WKHS 1
  • Target Price
  • APLM N/A
  • WKHS $15.62
  • AVG Volume (30 Days)
  • APLM 7.8K
  • WKHS 585.2K
  • Earning Date
  • APLM 08-13-2025
  • WKHS 08-19-2025
  • Dividend Yield
  • APLM N/A
  • WKHS N/A
  • EPS Growth
  • APLM N/A
  • WKHS N/A
  • EPS
  • APLM N/A
  • WKHS N/A
  • Revenue
  • APLM $198,000.00
  • WKHS $5,917,985.00
  • Revenue This Year
  • APLM $415.15
  • WKHS $54.16
  • Revenue Next Year
  • APLM N/A
  • WKHS $85.00
  • P/E Ratio
  • APLM N/A
  • WKHS N/A
  • Revenue Growth
  • APLM N/A
  • WKHS N/A
  • 52 Week Low
  • APLM $4.47
  • WKHS $0.81
  • 52 Week High
  • APLM $35.98
  • WKHS $28.13
  • Technical
  • Relative Strength Index (RSI)
  • APLM 47.85
  • WKHS 72.81
  • Support Level
  • APLM $6.21
  • WKHS $1.04
  • Resistance Level
  • APLM $6.80
  • WKHS $1.20
  • Average True Range (ATR)
  • APLM 0.52
  • WKHS 0.11
  • MACD
  • APLM 0.00
  • WKHS 0.05
  • Stochastic Oscillator
  • APLM 51.61
  • WKHS 81.26

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

Share on Social Networks: